Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Binimetinib and Pexidartinib in Advanced GIST
NCT03158103Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2017
- Primary completion
- Apr 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of binimetinib and pexidartinib in gastrointestinal stromal tumor (GIST), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Recommended phase II dose at 1 year. Started Apr 2017; status: completed.
02
Drugs
binimetinibpexidartinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT03158103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03158103.